Bio-Thera Solutions, Ltd., a leading innovative,
global biopharmaceutical company in Guangzhou, China, is dedicated to
researching and developing novel therapeutics for the treatment of cancer,
autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs,
as well as biosesimilars for existing, branded biologics to treat a range of
cancer and autoimmune diseases. As a leader in next generation antibody
discovery and engineering, the company has advanced multiple candidates into
late-stage development, including three approved products: QLETLI® (BAT1406) in China, and TOFIDENCE™/ BAT1806 and Avzivi® / Pobevcy® (BAT1706) in the US, EU and China. In addition, the company has more than
20 promising candidates in clinical trials, focusing on immuno-oncology in the
post-PD-1 era and targeted therapies such as ADCs.